118 related articles for article (PubMed ID: 8889695)
1. Molecular biology of MIS and its receptors.
Teixeira J; Donahoe PK
J Androl; 1996; 17(4):336-41. PubMed ID: 8889695
[TBL] [Abstract][Full Text] [Related]
2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
4. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
5. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
6. Müllerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies.
Shah PC; Simpson BB; Donahoe PK
Semin Pediatr Surg; 1996 Aug; 5(3):182-90. PubMed ID: 8858765
[TBL] [Abstract][Full Text] [Related]
7. Genetic studies of MIS signalling in sexual development.
Jamin SP; Arango NA; Mishina Y; Behringer RR
Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
[TBL] [Abstract][Full Text] [Related]
8. The müllerian inhibitor and mammalian sexual development.
Behringer RR
Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693
[TBL] [Abstract][Full Text] [Related]
9. Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor.
Imbeaud S; Faure E; Lamarre I; Mattéi MG; di Clemente N; Tizard R; Carré-Eusèbe D; Belville C; Tragethon L; Tonkin C; Nelson J; McAuliffe M; Bidart JM; Lababidi A; Josso N; Cate RL; Picard JY
Nat Genet; 1995 Dec; 11(4):382-8. PubMed ID: 7493017
[TBL] [Abstract][Full Text] [Related]
10. Müllerian inhibiting substance: new perspectives and future directions.
Catlin EA; MacLaughlin DT; Donahoe PK
Microsc Res Tech; 1993 Jun; 25(2):121-33. PubMed ID: 8518480
[TBL] [Abstract][Full Text] [Related]
11. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
[TBL] [Abstract][Full Text] [Related]
12. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
13. [Genetics and molecular pathology of anti-Mullerian hormone and its receptor].
Picard JY; Belville C
J Soc Biol; 2002; 196(3):217-21. PubMed ID: 12462075
[TBL] [Abstract][Full Text] [Related]
14. Paracrine-mediated apoptosis in reproductive tract development.
Roberts LM; Hirokawa Y; Nachtigal MW; Ingraham HA
Dev Biol; 1999 Apr; 208(1):110-22. PubMed ID: 10075845
[TBL] [Abstract][Full Text] [Related]
15. Mullerian inhibiting substance binding and uptake.
Catlin EA; Ezzell RM; Donahoe PK; Manganaro TF; Ebb RG; MacLaughlin DT
Dev Dyn; 1992 Apr; 193(4):295-9. PubMed ID: 1511169
[TBL] [Abstract][Full Text] [Related]
16. Anti-Müllerian hormone receptor defect.
di Clemente N; Belville C
Best Pract Res Clin Endocrinol Metab; 2006 Dec; 20(4):599-610. PubMed ID: 17161334
[TBL] [Abstract][Full Text] [Related]
17. Autosomal recessive segregation of a truncating mutation of anti-Müllerian type II receptor in a family affected by the persistent Müllerian duct syndrome contrasts with its dominant negative activity in vitro.
Messika-Zeitoun L; Gouédard L; Belville C; Dutertre M; Lins L; Imbeaud S; Hughes IA; Picard JY; Josso N; di Clemente N
J Clin Endocrinol Metab; 2001 Sep; 86(9):4390-7. PubMed ID: 11549681
[TBL] [Abstract][Full Text] [Related]
18. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L
J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623
[TBL] [Abstract][Full Text] [Related]
19. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of anti-Müllerian hormone (amh) and anti-Müllerian hormone receptor type II (amhrII) in the teleost medaka.
Klüver N; Pfennig F; Pala I; Storch K; Schlieder M; Froschauer A; Gutzeit HO; Schartl M
Dev Dyn; 2007 Jan; 236(1):271-81. PubMed ID: 17075875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
